Advertisement

Pathophysiology of Cancer Pain

  • Stephen Lawrence Thorp
Chapter

Abstract

Cancer pain is difficult to treat and a terrible malady for those suffering from cancer. Pain related to cancer is unique and may be related to the anatomic location of the tumor, the pathophysiology of the tumor, or the treatment of the cancer. The cause of the pain is multifactorial and may be somatic, visceral, neuropathic, or mixed in nature. Given the complexity of cancer pain, it is critical to assess the pathophysiology of the cancer and its role in creating a pain syndrome. Adequate control of pain may improve the patient’s quality of life through improved mood, functional status, and rest. As new therapies evolve, the treatment of cancer-related pain will continue to evolve as well, with the potential to create a new paradigm of treatment for our patients.

Keywords

Cancer pain Myeloma bone pain Tumor-induced plexopathy Tumor microenvironment Radiation-induced neuritis 

References

  1. 1.
    Merskey H, Bogduk N. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. Seattle: IASP; 1994. Print.Google Scholar
  2. 2.
    Van Den Beuken-Van Everdingen MHJ, Hochstenbach LMJ, Joosten BEAJ, Tjan-Heijnen VCG, Janssen DJA. Update on prevalence of pain in patients with Cancer: systematic review and meta-analysis. J Pain Symptom Manag. 2016;51(6):1070–90. n. pag. Web.CrossRefGoogle Scholar
  3. 3.
    Koizumi M, Yoshimoto M, Kasumi F, Iwase T, Ogata E. Post-operative breast Cancer patients diagnosed with skeletal metastasis without bone pain had fewer skeletal-related events and deaths than those with bone pain. BMC Cancer. 2010;10(1):423. Web.CrossRefGoogle Scholar
  4. 4.
    Fletcher CDM. WHO classification of tumours of soft tissue and bone. Lyon: IARC; 2013. Print.Google Scholar
  5. 5.
    Nencini S, Ivanusic JJ. The physiology of bone pain. How much do we really know? Front Physiol Front Physiol. 2016;7:157. n. pag. Web.PubMedGoogle Scholar
  6. 6.
    Mach DB, Rogers SD, Sabino MC, Luger NM, Schwei MJ, Pomonis JD, Keyser CP, Clohisy DR, Adams DJ, O’Leary P, Mantyh PW. Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience. 2002;113(1):155–66. Web.CrossRefGoogle Scholar
  7. 7.
    Jimenez-Andrade JM, Mantyh WG, Bloom AP, Haili X, Ferng AS, Dussor G, Vanderah TW, Mantyh PW. A phenotypically restricted set of primary afferent nerve fibers innervate the bone versus skin: therapeutic opportunity for treating skeletal pain. Bone. 2010;46(2):306–13. Web.CrossRefGoogle Scholar
  8. 8.
    Ohtori S, Orita S, Yamashita M, Ishikawa T, Ito T, Shigemura T, Nishiyama H, Konno S, Ohta H, Takaso M, Inoue G, Eguchi Y, Ochiai N, Kishida S, Kuniyoshi K, Aoki Y, Arai G, Miyagi M, Kamoda H, Suzkuki M, Nakamura J, Furuya T, Kubota G, Sakuma Y, Oikawa Y, Suzuki M, Sasho T, Nakagawa K, Toyone T, Takahashi K. Existence of a neuropathic pain component in patients with osteoarthritis of the knee. Yonsei Med J Yonsei Med J. 2012;53(4):801. Web.CrossRefGoogle Scholar
  9. 9.
    Arrington SA, Schoonmaker JE, Damron TA, Mann KA, Allen MJ. Temporal changes in bone mass and mechanical properties in a murine model of tumor osteolysis. Bone. 2006;38(3):359–67. Web.CrossRefGoogle Scholar
  10. 10.
    Jaeckle K. Neurologic manifestations of neoplastic and radiation-induced Plexopathies. Semin Neurol. 2010;30(03):254–62. Web.CrossRefGoogle Scholar
  11. 11.
    Jaeckle KA, Young DF, Foley KM. The natural history of lumbosacral plexopathy in cancer. Neurology. 1985;35(1):8. Web.CrossRefGoogle Scholar
  12. 12.
    Stevens MJ, Atkinson C, Broadbent AM. The malignant psoas syndrome revisited: case report, mechanisms, and current therapeutic options. J Palliat Med. 2010;13(2):211–6. Web.CrossRefGoogle Scholar
  13. 13.
    Fizazi K, Asselain B, Vincent-Salomon A, Jouve M, Dieras V, Palangie T, Beuzeboc P, Dorval T, Pouillart P. Meningeal Carcinomatosis in patients with breast carcinoma: clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer. 1996;77(7):1315–23. Web.CrossRefGoogle Scholar
  14. 14.
    Mehrabi A, Kashfi A, Fonouni H, Schemmer P, Schmied BM, Hallscheidt P, Schirmacher P, Weitz J, Friess H, Buchler MW, Schmidt J. Primary malignant hepatic epithelioid Hemangioendothelioma. Cancer. 2006;107(9):2108–21. Web.CrossRefGoogle Scholar
  15. 15.
    Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–37. Web.CrossRefGoogle Scholar
  16. 16.
    Hameed JB, Dowling P, Clynes M, O’Gorman P. Bone disease in multiple myeloma: pathophysiology and management. CGM Cancer Growth Metastasis. 2014;7:33. Web.Google Scholar
  17. 17.
    Edwards CM, Zhuang J, Mundy GR. The pathogenesis of the bone disease of multiple myeloma. Bone. 2008;42(6):1007–13. Web.CrossRefGoogle Scholar
  18. 18.
    Panis C, Pavanelli WR. Cytokines as mediators of pain-related process in breast cancer. Mediat Inflamm. 2015;2015:1–6. Web.CrossRefGoogle Scholar
  19. 19.
    Davidson ENB, Van Caam APM, Vitters EL, Bennink MB, Thijssen E, Van Den Berg WB, Koenders MI, Van Lent PLEM, Van De Loo FAJ, Van Der Kraan PM. TGF-β is a potent inducer of nerve growth factor in articular cartilage via the ALK5-Smad2/3 pathway. Potential role in OA related pain? Osteoarthr Cartil. 2015;23(3):478–86. Web.CrossRefGoogle Scholar
  20. 20.
    De Felice M, Lambert D, Holen I, Escott KJ, Andrew D. Effects of Src-kinase inhibition in cancer-induced bone pain. Mol Pain. 2016;12(0): n. pag. Web.Google Scholar
  21. 21.
    Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996;97(12):2692–6. Web.CrossRefGoogle Scholar
  22. 22.
    Kaiser T, Teufel I, Geiger K, Vater Y, Aicher WK, Klein G, Fehm T. Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast Cancer cells. Breast Cancer Res Treat. 2013;140(1):35–48. Web.CrossRefGoogle Scholar
  23. 23.
    Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2007;111(5):2516–20. Web.CrossRefGoogle Scholar
  24. 24.
    Fazzari J, Lin H, Murphy C, Ungard R, Singh G. Inhibitors of glutamate release from breast Cancer cells; new targets for Cancer-induced bone-pain. Sci Rep Sci Rep. 2015;5:8380. Web.CrossRefGoogle Scholar
  25. 25.
    Ungard RG, Seidlitz EP, Singh G. Inhibition of breast Cancer-cell glutamate release with sulfasalazine limits Cancer-induced bone pain. Pain. 2014;155(1):28–36. Web.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Pain MedicineNorthwell Health Phelps HospitalSleepy HollowUSA

Personalised recommendations